Steve Davis, Acadia Pharmaceuticals CEO

Aca­dia hits an­oth­er Nu­plazid road­block as the FDA doles out CRL and rec­om­mends an­oth­er tri­al

De­spite win­ning an ap­proval back in 2016, Aca­dia’s Nu­plazid has not had the eas­i­est of paths in its jour­ney to ex­pand in­to new ar­eas. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.